Skip To Main Content
Haolin Yin on Muck Rack

Haolin Yin

As seen in: Color Research & Application, Nature, Wiley Online Library, MDPI, ACS Publications, Journal of Chemical & Engineering Data, Seeking Alpha, Chemistry World
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Haolin

Contact Haolin, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

AllianceBernstein: Undervalued High-Yield Asset Manager With Durable Fee-Based Income

|
By Haolin Yin
| Seeking Alpha
Summary AllianceBernstein trades near its 52-week low at just ~10x forward earnings, offering an implied forward cash yield approaching 10%. The partnership's sustainable, though variable, distribution is supported by a diversified, recurring fee-based business, continued AUM growth, and meaningful exposure to fixed income. The proposed Equitable-Corebridge merger is a major catalyst, with more than $100 billion in assets expected to transition to AllianceBernstein's management.
Open in Who Shared Issue with article?

MapLight Therapeutics: The Cobenfy Challenger Does Not Look Like A Bargain

|
By Haolin Yin
| Seeking Alpha
Summary MapLight Therapeutics was assigned a Hold rating ahead of its Phase 2 ZEPHYR readout for ML-007C-MA in schizophrenia expected in mid-August. ML-007C-MA is positioned as a best-in-class challenger to Cobenfy, with differentiation in tolerability, dosing convenience, and potentially efficacy. ML-004 recently failed its primary endpoint in the autism indication, while meaningful improvement in a prespecified subgroup provided a path forward.
Open in Who Shared Issue with article?

Summit Therapeutics: High-Volatility, Catalyst-Driven Binary Bet

|
By Haolin Yin
| Seeking Alpha
Summary Summit Therapeutics is a highly volatile, single-asset company with a binary outcome. SMMT exhibits unusually concentrated ownership and heightened short interest, creating conditions for a short squeeze to take place. Recent pullbacks, driven by mixed market receptions to events do not fundamentally alter the investment narratives, present investors with an attractive entry point ahead of key catalysts.
Open in Who Shared Issue with article?
See all 20 articles